Title:
A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)
Indication:
Thrombocytopenia
Location:
Texas Oncology-McAllen
Phase: III
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
View
Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)
Indication:
Biliary Cancer
Location:
Texas Oncology-McAllen
Phase: II/III
Title:
Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract
View
Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)
Indication:
Biliary Cancer
Location:
Texas Oncology-McAllen
Phase: II/III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Biliary Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Bladder Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
PH1b/2 Durva+Pacl mTNBC(Begonia)
View
Description: A Phase IB/II 2-Stage Open-label Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer (D933LC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: I/II
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA)
View
Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)
View
Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Observational Study of patients initiating T-Dxd in HER2+ unresectable mBC (RESPOND)
View
Description: A multi-center multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+ and HER2-low unresectable and/or metastatic breast cancer (DESTINY BREAST- RESPOND) (D9673R00025)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas
View
Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)
Indication:
Breast Cancer
Location:
Texas Oncology-McAllen
Phase: I/II
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Cervical Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Colon Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas
View
Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)
Indication:
Colon Cancer
Location:
Texas Oncology-McAllen
Phase: I/II
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Endometrial Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Esophageal Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas
View
Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)
Indication:
Esophageal Cancer
Location:
Texas Oncology-McAllen
Phase: I/II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-McAllen
Phase: II
Title:
Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract
View
Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-McAllen
Phase: II/III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Gastric Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas
View
Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-McAllen
Phase: I/II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Hematologic
Location:
Texas Oncology-McAllen
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-McAllen
Phase: II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Leukemia
Location:
Texas Oncology-McAllen
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Liver Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC
View
Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: I/II
Title:
Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
View
Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
View
Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: II/III
Title:
STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
View
Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)
View
Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas
View
Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: I/II
Title:
ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer
View
Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)
Indication:
Lung Cancer
Location:
Texas Oncology-McAllen
Phase: III
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-McAllen
Phase: II
Title:
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
View
Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)
Indication:
Lymphomas
Location:
Texas Oncology-McAllen
Phase: I
Title:
Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas
View
Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)
Indication:
Lymphomas
Location:
Texas Oncology-McAllen
Phase: I/II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Melanoma
Location:
Texas Oncology-McAllen
Phase: IV
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Myelodysplastic Syndrome
Location:
Texas Oncology-McAllen
Phase: IV
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Myelomas
Location:
Texas Oncology-McAllen
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Ovarian Cancer
Location:
Texas Oncology-McAllen
Phase: II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Ovarian Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
View
Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-McAllen
Phase: II/III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-McAllen
Phase: II
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Prostate Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Rectal Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Renal Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Skin Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas
View
Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)
Indication:
Skin Cancer
Location:
Texas Oncology-McAllen
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C
View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Solid Tumors
Location:
Texas Oncology-McAllen
Phase: I/II
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-McAllen
Phase: I
Title:
STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
View
Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)
Indication:
Solid Tumors
Location:
Texas Oncology-McAllen
Phase: II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Solid Tumors
Location:
Texas Oncology-McAllen
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Thyroid Cancer
Location:
Texas Oncology-McAllen
Phase: IV
Title:
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
View
Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)
Indication:
Urothelial Cancer
Location:
Texas Oncology-McAllen
Phase: II/III
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-McAllen
Phase: I
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Waldenström macroglobulinemia
Location:
Texas Oncology-McAllen
Phase: II